Encouragingly, we have identified numerous cell type‐specific TGF‐β/Smad3 signaling pathways as novel and effective therapeutic targets for fibrotic diseases.[10, 14, 15, 18, 24, 26, 27] Therefore, we would extensively investigate the yet unexplored macrophage‐specific TGF‐β/Smad3 signaling pathways in lung cancer to identify potential therapeutic targets for precise inhibition of MMT formation in TME. Here, SMAD3 is linked to lung carcinoma.